Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 133-140 , April 2002

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

  • Marion de Jong

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • Corresponding Author InformationAddress reprint requests to M. de Jong, PhD, Department of Nuclear Medicine, Erasmus University Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
    • ,
  • Roelf Valkema

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • ,
  • Francois Jamar

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • ,
  • Larry K. Kvols

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • ,
  • Dik J. Kwekkeboom

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • ,
  • Wout A.P. Breeman

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • ,
  • Willem H. Bakker

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • ,
  • Chuck Smith

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • ,
  • Stanislas Pauwels

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
    • ,
  • Eric P. Krenning

      Affiliations

    • Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
    • Universitaire Catholique Louvain, Brussels, Belgium, USA
    • Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA

References 

  1. De Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437–441
  2. Kwekkeboom DJ, Bakker WH, Kooij PPM, et al. [177Lu-DOTA, Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–1325
  3. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D- Phe1]octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506
  4. De Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med. 1999;43:356–366
  5. Krenning EP, Valkema R, Kooij PP, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999;31(suppl 2):S219–S223
  6. Slooter GD, Breeman WA, Marquet RL, et al. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer. 1999;81:767–771
  7. (letter) Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–418
  8. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med. 1999;26:1439–1447
  9. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide: Preliminary report in cancer patients. Cancer Biother Radiopharm. 1999;14:477–483
  10. Stolz B, Weckbecker G, Smith-Jones PM, et al. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;25:668–674
  11. Valkema R, Jamar F, Jonard P, et al. Targeted radiotherapy with 90Y-SMT487 (OctreoTher): A phase I study. J Nucl Med. 2000;41:111P
  12. Erion JL, Bugaj JE, Schmidt MA, et al. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model. J Nucl Med. 1999;40:223P
  13. de Jong M, Breeman WA, Bernard BF, et al. [177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628–633
  14. Kwekkeboom DJ, Kam BL, Bakker WH, et al. Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors: Preliminary results. Eur J Nucl Med. 2001;28:1027P
  15. Patel YC, Greenwood MT, Panetta R, et al. The somatostatin receptor family. Life Sci. 1995;57:1249–1265
  16. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–198
  17. Schonbrunn A. Somatostatin receptors: Present knowledge and future directions. Ann Oncol. 1999;10(suppl 2):S17–S21
  18. De Jong M, Bernard BF, De Bruin E, et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0, Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 1998;19:283–288
  19. Andersson P, Forssell-Aronsson E, Johanson V, et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med. 1996;37:2002–2006
  20. Hofland LJ, van Koetsveld PM, Waaijers M, et al. Internalisation of isotope-coupled somatostatin analogues. Digestion. 1996;57(suppl 1):2–6
  21. Duncan JR, Stephenson MT, Wu HP, et al. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res. 1997;57:659–671
  22. Hornick CA, Anthony CT, Hughey S, et al. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 2000;41:1256–1263
  23. Bernard BF, Krenning E, Breeman WA, et al. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 2000;21:1079–1085
  24. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–282
  25. De Jong M, Breeman WAP, Bernard HF, et al. Tumor response after [90Y-DOTA0, Tyr3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med. 2001;42:1841–1846
  26. Stolz B, Smith-Jones P, Albert R, et al. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion. 1996;57(suppl 1):17–21
  27. Valkema R, Jamar F, Bakker WH, et al. Safety and efficacy of [Y-90-DOTA, Tyr(3)]octreotide (Y-90-SMT487; OCTREOTHER™) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study. Eur J Nucl Med. 2001;28:1025P
  28. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–434
  29. Otte A, Jermann E, Behe M, et al. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–795
  30. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol. 2001;12:941–945
  31. De Jong M, Breeman WAP, Bernard HF, et al. Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: Tumour size versus curability. Eur J Nucl Med. 2001;28:1026P
  32. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–1909
  33. van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 2000;90:186–198
  34. De Jong M, Bernard HF, Capello A, et al. RGD-DTPA-OCTREOTATE, an analogue for tumour imaging and radionuclide therapy. Eur J Nucl Med. 2001;28:1158P
  35. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review. Digestion. 2000;62(suppl 1):84–91

PII: S0001-2998(02)80031-9

doi: 10.1053/snuc.2002.31027

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 133-140 , April 2002

Article Tools